Sugi Predict

Sugi Predict / Compounds / SCHEMBL4147937

SCHEMBL4147937

SCHEMBL4147937

O=[N+]([O-])c1ccc2nc(-c3ccc(Br)cc3)cn2c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 11/20 0.77
▸ NPC1 O15118 10/20 0.77
▸ ALDH1A1 P00352 7/20 0.77
▸ SMN1; SMN2 Q16637 5/20 0.77
▸ POLB P06746 4/20 0.77
▸ GAA P10253 2/20 0.77
▸ CASP3 P42574 2/20 0.77
▸ SENP7 Q9BQF6 2/20 0.77
▸ SENP6 Q9GZR1 2/20 0.77
▸ LMNA P02545 2/20 0.77
▸ STAT3 P40763 1/20 0.77
▸ L3MBTL1 Q9Y468 1/20 0.77
▸ APP P05067 5/20 0.70
▸ KMT2A Q03164 7/20 0.65
▸ MEN1 O00255 6/20 0.65
▸ MAPT P10636 4/20 0.65
▸ PAX8 Q06710 2/20 0.60
▸ APEX1 P27695 1/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ HTT P42858 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1691646 0.99 RAB9A (0.75) RAB9ANPC1ALDH1A1SMN1; SMN2POLB
SCHEMBL5774975 0.91 RAB9A (0.68) RAB9ANPC1ALDH1A1SMN1; SMN2POLB
SCHEMBL10172979 0.91 RAB9A (0.86) RAB9ANPC1ALDH1A1SMN1; SMN2POLB
SCHEMBL9788664 0.87 RAB9A (1.00) RAB9ANPC1ALDH1A1SMN1; SMN2POLB
SCHEMBL13191467 0.86 RAB9A (0.77) RAB9ANPC1ALDH1A1SMN1; SMN2POLB
SCHEMBL2128686 0.86 RAB9A (0.77) RAB9ANPC1ALDH1A1SMN1; SMN2POLB
SCHEMBL2257167 0.86 RAB9A (0.77) RAB9ANPC1ALDH1A1SMN1; SMN2POLB
SCHEMBL11407545 0.85 RAB9A (0.76) RAB9ANPC1ALDH1A1SMN1; SMN2POLB
Bromide SCHEMBL1691440 0.84 RAB9A (0.75) RAB9ANPC1ALDH1A1SMN1; SMN2POLB
SCHEMBL1984138 0.81 RAB9A (0.84) RAB9ANPC1ALDH1A1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250101018-A1 HETEROARYL COMPOUNDS AND USES THEREOF APRINOIA THERAPEUTICS LIMITED (CN) 2025-03-27 — — US disclosed
US-12116364-B2 Heteroaryl compounds and uses thereof APRINOIA THERAPEUTICS INC. (CN) 2024-10-15 — — US disclosed
US-20230374006-A1 HETEROARYL COMPOUNDS AND USES THEREOF APRINOIA THERAPEUTICS LIMITED (CN) 2023-11-23 — — US disclosed
US-20230374006-A1 HETEROARYL COMPOUNDS AND USES THEREOF APRINOIA THERAPEUTICS LIMITED (CN) 2023-11-23 — — US disclosed
US-20230374006-A1 HETEROARYL COMPOUNDS AND USES THEREOF APRINOIA THERAPEUTICS LIMITED (CN) 2023-11-23 — — US disclosed
CN-112384517-B Heteroaryl compounds and uses thereof 新旭生技股份有限公司 2023-07-14 — — CN disclosed
US-20230047178-A1 HETEROARYL COMPOUNDS AND USES THEREOF APRINOIA THERAPEUTICS INC. (CN) 2023-02-16 — — US disclosed
US-20230047178-A1 HETEROARYL COMPOUNDS AND USES THEREOF APRINOIA THERAPEUTICS INC. (CN) 2023-02-16 — — US disclosed
US-20210253569-A1 HETEROARYL COMPOUNDS AND USES THEREOF APRINOIA THERAPEUTICS INC. (CN) 2021-08-19 — — US disclosed
US-20210253569-A1 HETEROARYL COMPOUNDS AND USES THEREOF APRINOIA THERAPEUTICS INC. (CN) 2021-08-19 — — US disclosed
WO-2019214681-A1 HETEROARYL COMPOUNDS AND USES THEREOF APRINOIA THERAPEUTICS INC. (CN) 2019-11-14 — — WO disclosed
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds CORFIELD JOHN ANDREW 2009-05-28 — — US disclosed
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds CORFIELD JOHN ANDREW 2009-05-28 — — US disclosed
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds CORFIELD JOHN ANDREW 2009-05-28 — — US disclosed
EP-1971599-A1 ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS SmithKline Beecham Corporation (US) 2008-09-24 — — EP disclosed
WO-2008029152-A2 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2008-03-13 — — WO disclosed
WO-2007071434-A1 ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-06-28 — — WO disclosed
WO-2007071434-A1 ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-06-28 — — WO disclosed
WO-2007039146-A1 4-CARBOXY PYRAZOLE DERIVATIVES AS ANTI-VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2007-04-12 — — WO disclosed
WO-2007039146-A1 4-CARBOXY PYRAZOLE DERIVATIVES AS ANTI-VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2007-04-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374006-A1 HETEROARYL COMPOUNDS AND USES THEREOF MAPT, APP, SLCO1B3 RAB9A 603/4885NPC1 88/4885ALDH1A1 1918/4885
US-20210253569-A1 HETEROARYL COMPOUNDS AND USES THEREOF MAPT, APP, SLCO1B3 RAB9A 603/4885NPC1 88/4885ALDH1A1 1918/4885
US-20230047178-A1 HETEROARYL COMPOUNDS AND USES THEREOF MAPT, APP, SLCO1B3 RAB9A 603/4885NPC1 88/4885ALDH1A1 1918/4885
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds EIF2AK2, HAVCR2, MAVS RAB9A 1920/4885NPC1 1833/4885ALDH1A1 1037/4885
US-20250101018-A1 HETEROARYL COMPOUNDS AND USES THEREOF MAPT, APP, SLCO1B3 RAB9A 603/4885NPC1 88/4885ALDH1A1 1918/4885
US-12116364-B2 Heteroaryl compounds and uses thereof MAPT, APP, SLCO1B3 RAB9A 603/4885NPC1 88/4885ALDH1A1 1918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.